Stock ANL ADLAI NORTYE LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Adlai Nortye Ltd.

Equities

ANL

US00704R1095

Delayed Nasdaq
Other stock markets
 15:30:49 2024-05-28 EDT 		5-day change 1st Jan Change
10.09 USD -3.88% Intraday chart for Adlai Nortye Ltd. -20.84% +12.27%
05-24 Adlai Nortye Ltd. Announces to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy At ASCO 2024 CI
04-08 ADRs Advance, Eco Wave Power Global AB Climbs 213.4% DJ

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024
GL
Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024
AQ
Adlai Nortye Ltd. Announces to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy At ASCO 2024
CI
Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy
GL
Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy
AQ
ADRs Advance, Eco Wave Power Global AB Climbs 213.4%
DJ
Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development
AQ
Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development
GL
Adlai Nortye Announces Appointment of Archie Tse as the Head of Research & Development
CI
Certain Class B Ordinary Shares of Adlai Nortye Ltd. are subject to a Lock-Up Agreement Ending on 28-MAR-2024.
CI
Certain Class A Ordinary Shares of Adlai Nortye Ltd. are subject to a Lock-Up Agreement Ending on 28-MAR-2024.
CI
Adlai Nortye : Term of use
PU
Adlai Nortye Says it has Completed Patient Enrollment in Phase 3 Trial of Buparlisib
MT
Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC
GL
Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC
AQ
Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC
CI
Cantor Fitzgerald Starts Adlai Nortye at Overweight With $30 Price Target
MT
Adlai Nortye Ltd. & Nucleai awarded ESMO 2023 BEST Poster Award
GL
Adlai Nortye : in collaboration with Nucleai, to Present "Utilizing H&E Images and Digital Pathology to Predict Response to Buparlisib in SCCHN" at ESMO 2023
PU
Adlai Nortye Ltd. Announces Closing of Initial Public Offering
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ANL Stock
  4. News Adlai Nortye Ltd.